Overview

Meningioma (disrupted in balanced translocation) 1 (MN1) is a gene that encodes a protein that may function in tumor suppression. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions and insertions are observed in cancers such as intestinal cancer, parathyroid cancer, and peritoneal cancer.

MN1 is altered in 0.15% of all cancers with breast invasive ductal carcinoma, colon adenocarcinoma, high grade ovarian serous adenocarcinoma, endometrial endometrioid adenocarcinoma, and lung adenocarcinoma having the greatest prevalence of alterations [3].

The most common alterations in MN1 are MN1-ETV6 Fusion (0.09%), MN1 V595M (1.06%), MN1 A85del (0.35%), MN1 A1192V (0.20%), and MN1 A1210P (0.85%) [3].

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.